Clinical characteristics and electroencephalogram analysis of levetiracetam in the treatment of children with febrile seizure recurrence

Abstract

Febrile seizure is the most common neurologic disorder in infants and children. This study aimed to elaborate safe and effective therapy for preventing FS recurrence by levetiracetam (LEV). A prospective study was performed in two groups of children, the no treatment group (n=51, 24.1±9.0 months) and the LEV treatment group (n=45, 23.3±8.9 months). The findings demonstrated that a significant difference (P<0.01) was observed between the no treatment group 51.0% (26/51) and LEV treatment group 15.5% (7/45) in terms of FS recurrence after 50 weeks. FS recurrence/fever episode was 12.4% (12/97) in the LEV treatment group and 51.8% (57/110) in the no treatment group. Furthermore, LEV administration significantly improved (P<0.001) epileptiform + nonspecific EEG abnormalities (17.8%; 8/45), as compared with the no treatment group (68.6%; 35/51). In conclusion, LEV could function as an effective therapeutic agent for the prevention of FS recurrence and reducing the frequency of fever episodes. Furthermore, LEV administration significantly improved nonspecific EEG abnormalities, which may be used as a clinical monitoring index for LEV treatment in patients with FS.

Guía clínica. Diagnóstico y tratamiento de crisis febriles

“…Las CFeS pueden ocurrir antes o después de que la fiebre sea aparente, dentro de 24 h, en el curso de una enfermedad febril [10][11][12] . Afectan al 2-5% de la población pediátrica y se ha reportado que son más frecuentes en algunos grupos étnicos asiáticos 3,13,14 . Son de carácter benigno, por ser convulsiones provocadas y no una epilepsia 7,13 .…”

“…Se encontró que el CLB es seguro, eficaz, requiere menos dosis y tiene menos efectos adversos que el DZP, sugiriéndolo como alternativa para la prevención de recurrencia de CFe 34 . Asimismo, en 2017 otros autores demostraron una diferencia significativa en la prevención de recurrencia con tratamiento con levetiracetam (LEV) frente a no tratamiento después de 50 semanas 14 (Tabla 5).…”

Clinical guideline: febrile seizures, diagnosis, and treatment

“…SFeS can occur before or after the fever becomes apparent, within 24 h, during the course of a febrile illness [10][11][12] . SFeS affect 2-5 % of the pediatric population and they are reported to be more frequent in some ethnic Asian groups 3,13,14 .…”